Investor presentationMar 2026
Mar 2026 · PPT
Source: Nse
Curis Lifesciences Ltd. (CURIS)
SME CapPharma stocks · SME cap · NSE
Curis Lifesciences Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityVerify one data layerQuote updated 21 Oct, 03:29 pm ISTPost-result recalculation pendingDetails
Quote21 Oct, 03:29 pm IST
Base fundamentals17 Oct 2026 · screener
Latest result02 Jun, 08:13 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage10/14 · 71%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
77BullishSMA20 +37.3% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
CURISD candles · FIT view+48.1%Latest close ₹185.00 on 2026-10-21
Daily history is available from 2025-11-14; the requested 1Y window is partially covered.
Bar
-0.5%
RSI
47
MACD hist
-6.09
52W pos
67%
2026-10-21O ₹185.90H ₹187.00L ₹180.65C ₹185.00Vol 6,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
CURISNifty PharmaNifty 500
- CURIS
- +67.4%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +73.9 pp
Chart stats
21 Oct 2026- From 52W high
- -21.2%
- 52W range position
- 67%
- ATR (14)
- 5.0%
- Volume vs 20D
- 0.62x
- Avg traded value
- ₹0.2 Cr
- 20D price channel
- ₹180.7 - ₹234.8
₹234.8
₹83.6 - ₹234.8
₹9.3
Latest completed session
20-session average
62.6% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST33
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bullish77
Price trend and sector-relative-strength timing.
Valuation
Legacy model+57.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence66
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹32.7 Cr | NDF | +17.2% |
| EBITDA | ₹5.1 Cr | NDF | -14.2% |
| Operating margin | 15.7% | NDF | -575 bps |
| PAT | ₹2.7 Cr | NDF | -35.6% |
| PAT margin | 8.3% | NDF | -680 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 30.00
- P/B
- —
- EV/EBITDA
- 17.65
- Market Cap
- 161.00Cr
Profitability
- ROE
- —
- ROCE
- —
- ROA
- —
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 0.45%
- EPS 5Y
- 335.77%
- Revenue 3Y
- 0.45%
- EPS 3Y
- 335.77%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- 9.93×
- Altman Z
- 0.00
- Book Value
- —
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- —
- EPS TTM
- 9.75
Shareholding
- Promoter Hold
- 68.03%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 76%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 60.6+20.6% vs prev
Net Profit
₹ CrLatest: 6.9+11.4% vs prev
Return on Equity
%Latest: 14.6-61.2% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 47. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~27.1% over last month) — short-term momentum positive.
- RSI(14) at 47 — falling, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 21% off 52W high · 121% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
96
RS percentile
Stage 2 UptrendEstablished S2
1M return
-5.2%
3M return
+86.1%
6M return
+101.5%
1Y return
-
RS 1D
0
RS 20D
+2
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is 46.2% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +11.5%.
- Both 3-month and 6-month returns are positive.
50-DMA
price above
200-DMA
price above
S2 entered
07 Sept 2026
S2 age
26 trading sessions
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
205 observations
21 Oct 2026Value 143.21-1.78%
RS vs Nifty 500143
Valuation & peers
U-Score 33 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 33 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation11/30
Growth18/25
Quality0/20
Balance Sheet9/15
Cash Flow0/10
Piotroski
5/9 (+3)
Penalties
-8
Raw sum
33
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
33/100 · legacy band WATCHLIST
Positive drivers
- Fair-value margin of safety is positive at 57.8%.
- Growth contributes 18/25 to the score.
- Balance sheet contributes 9/15 to the score.
Main drags
- Altman Z is 0.0, in distress territory.
- Penalty bucket subtracts 8 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
30.0
PB
—
EV/EBITDA
17.6
ROE
—
ROCE
—
FCF Yield
—
Debt/Equity
0.0
MoS
+57.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
33
Previous: 33
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+57.8%
Previous: +56.7%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
44
44
44
44
44
33
33
33
33
33
33
33
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
45.0
Growth-justified Value
₹438.75
+57.8% MoS
PEG
0.09
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
QUESTLAB
SME
Quest Laboratories Ltd.
Pharmaceuticals
match 164
70
11.3
16.6%
+78%
UNDERVALUED
ACCPL
SME
Accretion Pharmaceuticals Ltd.
Pharmaceuticals
match 163
58
22.2
27.6%
+51%
FAIR VALUE
SOTAC
SME
Sotac Pharmaceuticals Ltd.
Pharmaceuticals
match 162
55
17.5
10.1%
+62%
FAIR VALUE
ONYX
SME
Onyx Biotec Ltd.
Pharmaceuticals
match 161
15
—
-0.4%
—
OVERVALUED
BALPHARMA
Small
Bal Pharma Limited
Pharmaceuticals
match 161
23
23.6
7.9%
-44%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Curis Lifesciences Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
66Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 49th percentile of the scored universe and 36th percentile within Pharma. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
2 docs text-extracted · 2 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
49th percentile
overall median 67 · Pharma: 36th pctile, median 70 · SME: 60th pctile, median 64
Evidence depth
Financial-only
2 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
55
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 68%.
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.00.
Trust risks
- ▸Only 0 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Curis Lifesciences Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Annual reportMar 2026
Mar 2026 · Shareholders meeting 7 Sep - 10th AGM on 29 Sep 2026; FY2025-26 annual report submitted.
Source: Nse
Concall transcriptJan 2026
Jan 2026 · Transcript
Source: Nse
Concall transcriptJan 2026
Jan 2026 · Transcript
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.